

REVIEW

Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis

Herve Y Sroussi¹ , Joel B. Epstein^{2,3}, Rene-Jean Bensadoun⁴, Deborah P. Saunders^{5,6}, Rajesh V. Lalla⁷, Cesar A. Migliorati⁸, Natalie Heavilin⁹ & Zachary S. Zumsteg¹⁰ 

¹Division of Oral Medicine & Dentistry, Brigham and Women's Hospital Boston, MA

²Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA

³Division of Otolaryngology and Head and Neck Surgery, Duarte, California

⁴Centre de Haute Energie, 10, Bd Pasteur, 06000, Nice, France

⁵Department of Dental Oncology, Health Sciences North, Northeastern Cancer Centre, Sudbury, Ontario, Canada

⁶Northern Ontario School of Medicine, Rm 42036, Sudbury, Ontario, P3E 5J1, Canada

⁷Section of Oral Medicine, University of Connecticut Health, Farmington, Connecticut

⁸Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida, Gainesville, Florida

⁹Oral Maxillofacial Surgery Department, University of California, San Francisco, California

¹⁰Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California, 90048

Keywords

Fibrosis, head and neck cancer, neurosensory disorder, oral candidiasis, oral health, oral mucositis, radiation therapy

Correspondence

Herve Sroussi, Division of Oral Medicine & Dentistry, Brigham and Women's Hospital, Boston, MA 02120. Tel: 617-5256864; Fax: 617-232-8970; E-mail: hsroussi@partners.org

Funding Information

No funding information provided.

Received: 31 March 2017; Revised: 1 September 2017; Accepted: 1 September 2017

Cancer Medicine 2017; 6(12):2918–2931

doi: 10.1002/cam4.1221

Abstract

Patients undergoing radiation therapy for the head and neck are susceptible to a significant and often abrupt deterioration in their oral health. The oral morbidities of radiation therapy include but are not limited to an increased susceptibility to dental caries and periodontal disease. They also include profound and often permanent functional and sensory changes involving the oral soft tissue. These changes range from oral mucositis experienced during and soon after treatment, mucosal opportunistic infections, neurosensory disorders, and tissue fibrosis. Many of the oral soft tissue changes following radiation therapy are difficult challenges to the patients and their caregivers and require life-long strategies to alleviate their deleterious effect on basic life functions and on the quality of life. We discuss the presentation, prognosis, and management strategies of the dental structure and oral soft tissue morbidities resulting from the administration of therapeutic radiation in head and neck patient. A case for a collaborative and integrated multidisciplinary approach to the management of these patients is made, with specific recommendation to include knowledgeable and experienced oral health care professionals in the treatment team.

Introduction

Cancer patients undergoing radiation therapy (RT) of the head and neck encounter acute and chronic changes to their soft tissue as well as transient and permanent sensory disturbances. In addition, RT results in a deterioration in dental and periodontal health as well as a risk of

osteoradionecrosis. The acute effects of RT include mucositis, thickened secretions, mucosal infections, pain, and sensory disruptions. The long-term chronic effects of head and neck RT comprise tissue fibrosis, salivary gland dysfunction, increased susceptibility to mucosal infections, neuropathic pain, sensory disorders and an increased susceptibility to dental caries and periodontal disease. The

purpose of this article is to describe some of the common complications of head and neck radiation during and following cancer therapy and to discuss management strategies based on evidence and on the clinical experience of the authors.

Mucositis

Oral mucositis (OM) is an acute response to treatment that affects the majority of the patients receiving RT for head and neck cancer (HNC) [1]. In patients receiving a typical 6–7 week course of RT, OM presents as erythema of the oral mucosa in the first 2–3 weeks of RT and progresses to ulceration and pseudomembranes (Fig. 1) as the dose of radiation increases. Mucositis may be evaluated using mucositis scales such as the World Health Organization (WHO) mucositis scale, the National Cancer Institute (NCI) scale for oral mucositis and the Common Terminology Criteria for Adverse Events (CTCAE) (Table 1). The WHO mucositis scale is the most commonly used scale in clinical and research settings, whereas the NCI CTCAE scale is often used as a measure of overall toxicity. Other validated scales are available, and are primarily used in clinical research studies of mucositis (e.g.: OMAS Scale) [2]. Although the anatomic distribution of mucositis is predominantly related to the radiation dose distribution, nonkeratinized oral tissues (buccal mucosa, lateral tongue, soft palate, floor of mouth) are more susceptible to OM than keratinized oral tissues [3]. For HNC patients receiving concurrent chemotherapy and RT, OM may be more severe, appears earlier in the treatment course, and is of longer duration. Targeted therapies (e.g., epidermal growth factor inhibitors) amplify OM [4],




Figure 1. Oral Mucositis lesion on the buccal mucosa of a patient receiving radiation therapy to the head and neck region. Note the central area of ulceration covered by a whitish pseudomembrane, and the surrounding erythematous area. Picture from the teaching collection of Dr. Rajesh V. Lalla.

Table 1. The World Health Organization Oral Mucositis Scale and The National Institute of Health Common Terminology Criteria for Adverse Events.

Grade	Description
(A)	
0 (none)	None
I (mild)	Oral soreness, erythema
II (moderate)	Oral erythema, ulcers, solid diet is tolerated
III (severe)	Oral ulcers, only liquid diet is possible
IV (life-threatening)	Oral alimentation is impossible
(B)	
0	None
1	Asymptomatic or mild symptoms; intervention not indicated
2	Moderate pain; not interfering with oral intake; modified diet indicated
3	Severe pain; interfering with oral intake
4	Life-threatening consequences; urgent intervention indicated
5	Death

(A) Adapted from WHO Handbook 1979, pp. 15–22; (B) Adapted from NIH CTCAE v4.03 (2010) p. 45.

and may cause dermatitis and resulting in extension to sites beyond the high-dose RT fields.

It is also important to assess patient reported outcomes (PROs), using validated scales such as: Vanderbilt Head and Neck Symptom Survey (VHNSS), Patient-Reported Oral Mucositis Symptoms (PROMS), University of Washington-QOL (UWQoL), Eastern Cooperative Oncology Group (ECOG), Functional Assessment of Cancer Therapy – Head and Neck (FACT-HN) [1, 5]. The scale with broadest coverage of oral and head and neck symptoms is the VHNSS. The scale chosen is based upon the nature of the treatment provided and the potential goal of research and clinical care. The PROMs scale has been evaluated for use in settings where specific oral evaluation is not conducted and addresses mucositis specifically [6].

OM can peak near the end of RT and continue for 2 to 4 weeks post-RT [7, 8], with recovery over several weeks, depending on the severity of the lesions and the addition of chemotherapy or targeted therapy. Diagnosis of OM is usually made clinically. However, secondary infection such as candidiasis or Herpes simplex virus (HSV) infection should be considered if the clinical appearance is unusual or duration is prolonged. The diagnosis of complicating infection can be challenging.

The primary morbidity of OM is pain associated with erythema and ulcerative lesions. Pain may lead to significant functional compromise affecting oral functions including nutrition. This may result in weight loss that may require use of a gastrostomy tube [9]. Quality of life is significantly compromised by OM [1, 8]. Severe OM may lead to emergency room visits, hospital admission and

undesirable breaks in RT or discontinuation of planned chemotherapy. This may compromise the outcome of cancer therapy and increases the cost of care [9, 10].

Management of OM in HNC RT patients remains largely symptomatic. Many centers use a locally-compounded mouth rinse (often referred to as “magic mouthwash”) containing lidocaine, often in combination with other ingredients such as diphenhydramine, a coating agent such as Maalox®, and occasionally an antifungal. However, mixing several active ingredients results in dilution of each agent and potential incompatibility of products that reduce their overall efficacy, and furthermore, there is limited clinical evidence that magic mouthwash is efficacious [11]. In contrast, other agents, such as doxepin [12], palifermin [13, 14], benzydamine [15], and certain proprietary coating agents [16], have shown benefit in reducing mucositis pain in randomized controlled trials. Topical use of analgesics may be helpful and provide longer duration of pain relief; however systemic analgesics may be needed for pain management (see below). Evidence-based clinical practice guidelines for OM have been published by the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) [3]. These guidelines include recommendations (based on higher level evidence), suggestions (based on lower level evidence), or a determination of “no guideline possible” (based on inadequate or conflicting evidence). Guidelines relevant to HNC RT-induced OM are discussed below with the specific Level of Evidence (LOE) listed in brackets and can be found at <http://www.mascc.org/mucositis-guidelines>. MASCC/ISOO guidelines for oral mucositis and other toxicities of RT are also included in the “RadOnc Toolbox,” an app that will shortly be released by the Radiation Oncology Institute/ASTRO.

1. Oral Care: Standardized oral care protocols are recommended to prevent oral mucositis in all age groups and across all cancer treatment modalities (LOE III) [17].
2. Pain Control: It is suggested that 0.2% morphine mouthwash (LOE III) and 0.5% doxepin mouthwash (LOE IV) may be used for pain management due to OM in head and neck RT patients [17]. No recommendation was possible for the use of combination mouthwashes (“magic mouthwash”) containing lidocaine and other ingredients, due to inadequate evidence.
3. Benzydamine: It is recommended that benzydamine mouthwash (anti-inflammatory [not approved for mucositis in USA]) be used to prevent oral mucositis in patients with HNC receiving moderate dose RT (up to 50 Gy), without concomitant chemotherapy (LOE I). Benzydamine has not been adequately studied in RT with concomitant chemotherapy [12].
4. An additional study supports the use of benzydamine for patients receiving higher radiation dosage (≥ 50 Gy) with significant reduction in mucositis score starting at week 4 of the radiation treatment [15].
5. Low-level laser therapy (LLLT) [photobiomodulation]: It is suggested that LLLT (wavelength 620–810 nm) be used to prevent OM in patients undergoing RT, without concomitant chemotherapy, for HNC (LOE III). No guideline was given for patients receiving concomitant chemotherapy, due to limited evidence [18]. The mechanisms may include anti-inflammatory and analgesic effects as well as promotion of healing [19, 20].
6. Zinc: It is suggested that systemic oral zinc supplements may be of benefit for preventing OM in oral cancer patients receiving RT or chemoradiation (LOE III). The mechanism may include promotion of wound healing [21].

The MASCC/ISOO guidelines also provide guidelines against the use of agents shown to be ineffective. For HNC RT patients, the use of sucralfate mouthwash (coating agent), topical antimicrobials (polymyxin, tobramycin, amphotericin B; bacitracin, clotrimazole, gentamicin), chlorhexidine mouthwash (antimicrobial), misoprostol mouthwash (anti-inflammatory), and systemic pilocarpine (saliva stimulant) was not recommended [13, 22, 23]. It should be noted that while these agents are not recommended for OM, some of these agents may have application for other indications in this population.

Oropharyngeal candidiasis

Oropharyngeal candidiasis (OPC) is common in HNC patients (Fig. 2). OPC is associated with mucosal pain, taste change and can extend to the esophagus and result in dysphagia; in addition to oropharyngeal symptoms, oral



Figure 2. Head and neck cancer patient at 25/35 fraction with dry ropery saliva, oral mucositis, and suspected oral candidiasis. Picture from Dr. Deborah Saunders.

intake can be adversely affected affecting nutritional status and ability to take oral medications. Regional extension or systemic dissemination may occur in myelo/immunosuppressed patients. Clinical presentation includes pseudomembranous (thrush) and erythematous candidiasis, and angular cheilitis. Hyperplastic (nodular) and invasive candidiasis are less common and may require biopsy for diagnosis.

Candidiasis has variable symptoms: from no symptoms to burning sensitivity and pain, a sensation of coating in the mouth, odynophagia, dysgeusia (often described as a metallic taste), and smell of yeast infection. Diagnosis can be challenging, because the symptoms may overlap with those of mucositis. In some cases, differentiation between candidiasis and mucositis can be made by the presence of angular cheilitis, erythema, and pseudomembranes outside of the high-dose radiation volume. The differential diagnosis of fungal glossitis includes geographic tongue, lichen planus, erythema multiforme, herpetic lesions, leukoplakia, oral hypersensitivity, denture reaction, and hairy leukoplakia. Microbiological study is not diagnostic of infection as, the presence of noninvasive yeast in the oral cavity may simply represent a carriage state frequently seen in healthy people [24]. Organism identification may be needed in resistant infection and to confirm the clinical diagnosis. It is not uncommon to evaluate the response to antifungal treatment as a diagnostic strategy to rule out oral candidiasis.

Current guidelines for management of OPC derive primarily from clinical trials in immunosuppressed HIV patients [25]. Topical oral treatments are recommended as first-line therapy in milder forms of candidiasis [26]. Topical azole or polyene antibiotics in the form of a lozenge, suspension or cream may be applied intra-orally. Instructions include applying nystatin and amphotericin B (available in Europe) [27] four to six times daily, maintaining contact time on the mucosa as long as possible. It should be noted that the use of amphotericin B lozenges did not perform as well as systemic fluconazole in this comparative study [27]. Some products, including oral rinse forms of nystatin that contain sugar, leads to increased caries risk particularly in dentate patients with hyposalivation [28, 29]. Topical fluconazole rinses can be compounded and have been examined and shown effective in cancer patients with candidiasis. Topical clotrimazole is available in a lozenge and cream but the assumption that it use as a topical agent completely avoids concerns of systemic exposure and drug-drug interactions is not supported by reports of such complications [30]. Topical miconazole is available in cream form, and in a muco-adhesive tablet (Loramyc® EU; Oravig® USA) that does not have sugar sweetening used once daily and has a broad spectrum of activity against *Candida* species [26].

Systemic treatments should be used in case of failure of local treatment or immediately with severe clinical OPC in high risk (myelosuppressed, immunocompromised) patients. In general, systemic therapy with fluconazole (Triflucan®, Diflucan®) is superior to topical antifungals in cancer patients [31]. Among the systemically used azoles, fluconazole appears to have the fewest drug interactions. The Infectious Diseases Society of America recommends 200 mg on day one (loading dose) followed by 100 mg/day for OPC [27]. Fluconazole can be used for prophylaxis in cases with frequent recurrences using 50–200 mg/day or 100–400 mg/week, and has been shown superior to oral polyenes [32]. Nicolatou-Galitis et al. demonstrated a significant reduction in candida carriage and an elimination of oral candidiasis together with a significant reduction in severe mucositis and treatment interruption at the end of RT in subjects randomized to a group receiving a daily dose of 100 mg fluconazole when compared to controls [33]. The effectiveness of this approach has yet to be confirmed by others and it is not widely implemented. If candidiasis develops during RT, antifungal therapy should continue until completion of planned RT and patients should also be followed after completion of RT to determine if candidiasis recurs in order resume therapy or institute preventive protocols. However, the widespread use of fluconazole has been associated with the emergence of fluconazole resistant fungi [34]. Voriconazole and posaconazole have demonstrated efficacy in esophageal candidiasis in immunocompromised patients but is not recommended for use for treatment of initial or mild cases of OPC. A Cochrane review of management of candidiasis in cancer patients receiving radiation and/or chemotherapy did not identify sufficient evidence to support the use of current interventions in treating oral candidiasis recommending that additional studies be conducted to address this gap of knowledge [35].

The use of chlorhexidine is not recommended for management of mucositis, but may have value as a broad spectrum antiseptic to control microbial risk of dental and gingival disease and has limited antifungal activity [36]. If used in patients with oral mucositis formulations without alcohol are needed.

Neurosensory disorders: mucosal pain and taste dysfunction

Mucosal pain that affects diet and quality of life occurs during active cancer therapy and is a common chronic complaint in survivors [37]. Mucosal pain may be related to inflammation, ulceration, mucosal atrophy or mucosal neuropathy and may be compounded by dry mouth and potentially secondary infection. Radiation-induced neuropathies may be caused by neurotoxicity, ischemia,

oxidative stress, and inflammation [38]. The onset of neuropathic symptoms is variable beginning during cancer therapy or may be delayed in onset. Mucosal sensitivity may persist long after clinical mucositis resolves and is common at one-year follow-up and reported in up to two-thirds of patients [39]. A number of chemotherapeutic agents used in HNC may lead to neuropathy, including platinum agents, taxanes, fluorouracil and targeted agents. [40]. Targeted chemotherapy may cause mucosal ulceration (aphthous-like) and neurotoxicity resulting in pain which may represent the treatment limiting toxicity [41]. Immunotherapies (immune check point inhibitors) may stimulate immune/inflammatory processes leading to pain in the oral mucosa and oropharynx [42].

Pain prevention and management will improve with further understanding of the molecular and neurophysiologic mechanisms underlying the painful condition (Tables 2 and 3) [43, 44]. Current management follows guidelines of WHO analgesic ladder with reduced emphasis on opioid analgesics, which have limited effect on neuropathic pain, and a focus on adjunctive centrally-acting medications and pain management strategies (Table 4). Such factors as serotonin, norepinephrine, substance P, calcitonin gene related peptide, N-methyl D-aspartate, prostaglandins, COX-2, tumor necrosis factor- α , vascular endothelial growth factor, nerve growth factor, altered tissue pH, interleukins and nociceptor sensitization and stimulation may represent potential targets of therapy.

There is no proven prophylaxis for mucosal pain, although it is anticipated that less severe mucositis and reduced duration of ulceration may lead to reduced risk of long-term mucosal sensitivity. Current management of persisting neuropathic pain associated with or following mucositis relies upon neurologically active medications including clonazepam, gabapentin, pregabalin, duloxetine, and tricyclics. Topical delivery may be considered when local sensitivity is seen. Other approaches include acupuncture and low-level laser therapy (photobiomodulation) [45, 46].

Table 2. Mechanisms of Mucosal pain in oncology.

Processes		
Radiation therapy	Acute	Mucositis, infection, molecular sensitization and stimulation
	Chronic	Neuropathy, atrophy, hyposalivation, ischemia, fibrosis; molecular sensitization and stimulation
Chemotherapy/targeted therapy, immunotherapy	Acute	Mucositis; infection, molecular sensitization and stimulation
	Chronic	Neuropathy, fibrosis; molecular sensitization and stimulation

Table 3. Potential molecular sensitizers and mediators of pain.

Neurotoxicity/neuropathy
Radiation, chemotherapy, targeted therapies
Cellular necrosis and apoptosis:
Cell contents $\uparrow$ inflammation, nociception
Tumor acidity, inflammation $\downarrow$ pH, proton induced pain
Inflammatory mediators: damaged tissue and inflammation
Cytokines/growth factors:
Tumor Necrosis factor (TNF), interleukins (IL-1, IL-6), Platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor (TGF), vasoactive intestinal peptide (VIP), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), endothelins, others
Sensory Neurotransmitters:
Serotonin, noradrenaline, bradykinin, substance P, Calcitonin gene related peptide (CGRP), excitatory amino acids (e.g., glutamate; activation N-methyl-D-aspartate receptors), protons, reactive oxygen species
Inflammatory mediators:
Proinflammatory cytokines, histamine
Arachadonic acid metabolites: prostaglandins, leukotrienes, adenosine, adenosine 5'-triphosphate, nitric oxide
Other:
Infection:
Microbial waste products, pH, increase inflammation, proinflammatory cytokines, inflammatory cell activity

HNC RT and chemotherapy may directly modify smell and taste sensations [47]. RT may cause neuroepithelial damage and chemotherapy and targeted therapy may also result in a dysgeusia or ageusia and mucosal sensitivity [48]. Taste disorders occur in more than 75% of HNC patients receiving RT [49]. The recovery of taste

Table 4. Management of oral mucosal pain.

Symptom management:
Topical agents: anesthetics, analgesics, neurologically active medications
WHO ladder:
Analgesics (prostaglandins, COX2)
Nonsteroidal analgesics, acetaminophen
Mild opioid combination agents
Strong opioids and nonsteroidal analgesics, acetaminophen
Adjunctive Centrally acting medications:
Anticonvulsants
Antidepressants
Tricyclics, gabapentinoids, serotonin norepinephrine reuptake inhibitors
Anxiolytics; sleep promoters
Adjunctive techniques:
Acupuncture, low-level laser therapy (LLLT), psychological techniques
Psychological:
Cognitive/behavioral therapy
Distraction techniques
Relaxation/ imagery techniques
Music therapy; drama therapy
Counseling

following RT is variable. In some cases improvement is noted within 2–6 months after treatment, but in some, the changes may continue ad infinitum [49–52]. Flavor is a combination of taste, smell, texture, and temperature. Flavor impacts food choices, food intake, and therefore influences nutritional status. Taste is a complex sensation, based upon five basic qualities (sweet, bitter, salt, sour, and umami [savory]). In addition, fat “taste,” spicy “sensation” and metallic taste may play a role mediated by receptor transduction, nonspecific transport across the cell membrane [51] and may stimulate a chemosensory response which may enhance flavor and be important in energy intake. Small C-fiber function mediates sensations that are a component of taste including capsaicin (hot-spicy sensation), piperine (pungency of black pepper), and zingerone (perception of ginger), as well as sensations induced by menthol (cooling sensation) [51]. Change in C-fiber and A-delta fibers in mucosal sensitivity may impact taste.

Taste and flavor have had limited study in cancer therapy. In addition to RT, chemotherapy and targeted therapeutics may affect taste by direct taste receptor stimulation, or damage, or via secretion in saliva or gingival crevicular fluid [52]. Hyposalivation and oral, dental, periodontal, and oropharyngeal pathologies may affect taste function and mucosal sensitivity [53, 54]. It should be recognized that systemic factors can influence taste such as paraneoplastic syndromes [55], diabetes, severe anemia, and leukemia [56]. In addition, medications may have taste-related side effects, with the highest prevalence rates of taste change associated with antibiotics, anti-hypertensives, antidepressants, muscle relaxants, and multiple cancer chemotherapeutics including cytotoxic, targeted and immune therapies [57].

All taste qualities are affected with RT to the oral cavity. Initially, sweet perception may decrease, resulting in symptoms of increased bitter and salt taste, followed by general abnormal taste and reduction in taste perception [58, 59]. Umami taste may decrease during RT and recovery of umami taste may be delayed and continue indefinitely. Loss of umami taste is important because it may reduce interest in eating and negatively impact quality of life [51]. Damage to C-fibers may result in mucosal sensitivity and change in taste.

Management includes dietary counseling with guidance in food choices, food preparation and seasoning (increase spice if tolerated, increase umami foods, and umami flavoring), and avoiding unpleasant foods. Zinc sulfate supplementation has been therapeutically tested with inconsistent outcomes in clinical studies [60, 61]. Centrally acting medications have received limited study to date, but early suggestions include: clonazepam, gabapentin, cannabinoids, and megestrol [61].

Post radiation fibrosis

Late effects from HNC RT may involve several different structures in the regions that were irradiated. In particular, radiation to the neck may cause damage to the vessels, nerves, and muscles. Moreover, damage to the lymphatics, which drain fluid from the head and neck, may cause lymphedema. Fibrosis in lingual muscles as well as constrictor muscles of the pharynx can follow therapy and may affect tongue function and swallowing, respectively. Fibrosis in masticatory muscles, particularly lateral pterygoids can result in trismus.

Trismus, temporomandibular disease, and fibrosis limiting function of the lips and tongue may develop as late RT side effects. RT to the muscles of mastication (masseter, temporalis, and the medial and lateral pterygoids) and region of the temporomandibular joint [62] causes inflammatory changes which can lead to muscle fibrosis [63]. Trismus can lead to difficulty in eating, swallowing, speech, general oral hygiene and access for use of dental prosthesis and delivery of dental care.

The incidence of radiotherapy-induced trismus (RTIT) in HNC patients varies greatly in older studies, ranging between 5% and 45% which may be largely attributed to a lack of uniform criteria for RTIT and changes in RT technique [64]. A cut-off point of <35 mm for mouth-opening was introduced in 2006 and has been used as a standard for trismus in latest studies [65]. The incidence of trismus is decreasing with intensity-modulated radiotherapy (IMRT) for most HNC patients receiving curative radiation treatment. Similarly, pharyngeal constrictor muscle damage has decreased with the last generation of IMRT machines. A systematic review of 12 articles from 1990 to 2008 [66] reported the weighted prevalence for RTIT to be 25% in patients receiving three-dimensional conventional radiotherapy (3D-CRT), 5% for IMRT, and 31% in combined CRT and 3D-CRT. The authors argued that the effects of RT are cumulative with an initially slow onset and that RTIT may begin soon after the end of RT or at any time up to 2 years posttreatment with variable progression remain the same or improve over time [66].

Although RTIT has been documented in the literature for decades, research on prevention and treatment is limited. Two systematic reviews from 2004 and 2010, one researching the effect of different cancer treatments on the prevalence of trismus [64], and the other attempting to identify criteria, risk factors and treatment interventions for trismus [66], concluded that there is a need for appropriately powered, prospective randomized studies to better understand and manage RTIT.

Pentoxifylline and vitamin E may reduce treatment related fibrosis, but the level of evidence was not sufficient

for guideline use [66]. Use of a device developed for trismus (TheraBite® Jaw Motion Rehabilitation System) was suggested due to low level evidence in favor of use.

The efficacy of Low Level Light Therapy (LLLT) or photobiomodulation has potential application for prevention and treatment of RTIT and is now evaluated in several clinical studies [67]. While international evidence-based guidelines for patients with HNC experiencing RTIT are lacking [67], clinical regional guidelines have been developed, suggesting that RTIT may be prevented by active, passive and supportive stretching of the muscles of mastication during RT.

Dental caries

Patients are at increased risk of dental caries following RT primarily due to hyposalivation [68]. Saliva has essential functions in maintaining tooth structure due to control of pH, remineralization and antimicrobial and tooth cleansing effects [69]. Dental caries results from a loss of equilibrium in tooth demineralization-remineralization culminating in mineral loss leading to damage to the organic phase of tooth structures, resulting in cavitation. Demineralization first appears as increased white lesions involving gum line regions and cusp tips of the teeth. Untreated caries can progress rapidly and require more extensive treatment making prevention and early detection of mineral loss essential. Sequelae include pain, infection of the jaw bone, and potentially the need for tooth extraction and in patients who have high-dose RT to the region, resulting in risk of osteoradionecrosis.

The prevalence of caries in patients who have received RT depends on the cohort, but averages well above 25% [70]. The risk of caries in cancer survivors has been shown to correlate with the dose of RT to the parotid glands, [71, 72] and it is expected that parotid sparing regimen will reduce the risks of caries. Hey et al. [72] reported that patients who did not experience new carious lesions 24 months after RT received a statistically lower RT dose (21.2 ± 11.4 Gy) compared to patients with sporadic (26.5 ± 11.59 Gy) or generalized caries lesions (33.9 ± 9.93 Gy). Increase in the incidence of carious lesions correlated with decline in stimulated whole saliva secretion. While data on submandibular gland exposure is limited, it is anticipated that function of these glands are also important in maintaining dental health. Irradiation of the salivary glands results in hyposalivation, and causes changes in the composition of saliva [73], decreasing its ability to prevent dental demineralization.

The term “radiation caries” [74] has been used to describe rampant caries following HN RT. Although radiation can directly affect the structure and mechanical properties of teeth [75, 76], there is little evidence that

the pathogenesis of radiation caries is different from that of the classical caries in other patient populations with hyposalivation. In addition, radiation caries appear clinically similar to nonradiation related caries seen in dry mouth patients [76]. However, radiation associated caries develop more rapidly and are more likely to include non-classical surfaces of teeth (cusp tips, gum line cavities) when compared to classical caries. Radiation caries are also associated with a higher rate of recurrence and a greater risk of failure of the dental treatment requiring additional dental procedures [77]. The increased risk is related to demineralization, shift to a more cariogenic oral flora, difficulty in oral hygiene and possible shift to a diet high in carbohydrates [78].

In our experience, it is recommended that patients who have or will undergo RT maintain an aggressive comprehensive oral health management plan. This includes regular dental care which will allow early identification of demineralization and carious lesions and fluoride and calcium applications to support dental remineralization. While fluoride delivered in application trays to the teeth is considered the most effective means of application, different methods of fluoride application are available and comparative effectiveness for fluoride application methods is not documented. The application of fluoride can be accomplished in professionally applied fluoride varnishes, with mouth washes, high fluoride prescription toothpaste, complex fluoride slow-release devices [79, 80]. The latter technique may be cumbersome and expensive without necessarily yielding better results than simple fluoride trays. Fluoride applications must be continued as long as hyposalivation persists. If the patient is not compliant with the use of fluoride carriers, brush on fluoride on teeth twice daily and other cavity prevention (i.e., diet modifications) must be undertaken.

Early detection of caries through dental follow up visits every 6 months are recommended to preserve oral health. More frequent follow-ups may be necessary depending on persistence of hyposalivation and the presence/progression of dental demineralization, caries, and periodontal status.

In patients with documented demineralization of teeth, and if saliva production is reduced, use of remineralizing products (calcium and phosphate) are necessary to provide building blocks of teeth in addition to topical fluoride [81]. The use of antiseptic chlorhexidine to reduce cariogenic microbial load [82] and sialagogues [83, 84] to stimulate salivary flow should also be considered. Stimulation of salivary production may be achieved in patients with residual saliva production using sugar-free or alcohol-substituted sugar (e.g., xylitol) lozenges, which may be supplemented with fluoride or other elements for caries prevention [85]. Dietary and oral hygiene

counseling [83] is a critical part of the management of patients before, during, and after RT of the head and neck. The inclusion of the proactive dental management plan described above, together with an effort to spare salivary function and to stimulate residual gland function, can improve caries control [86] in high-risk oncology patients. This requires the awareness of the oncology team of the patient's oral health needs as well as the training of dentists in delivering care to the oncology patient, as general dentists may feel ill equipped and reluctant to treat these patients [87].

Periodontitis

Periodontitis is a highly prevalent and chronic microbial/inflammatory disease which is characterized by the loss of tooth-supporting tissue inclusive of the tooth supporting alveolar bone. Periodontitis may culminate in pain, infection of the jaw bones around dental roots, and tooth loss. In HNC patients, periodontitis may be a trigger of osteoradionecrosis (ORN) (see below) [88]. Patients receiving radiation for head and neck cancers are at an increased risk for periodontal disease compared to the general population for several reasons. Hyposalivation and the loss of the protective effects of saliva may predispose to periodontitis. Furthermore, the use of RT in the head and neck region causes changes in the oral microbiome, with a shift to periodontal disease-associated flora [78, 89]. Consistently, rapid loss of tooth-supporting tissue was noted by Ammajan et al. [90] who reported a significant loss in periodontal attachment level as well as gingival recession when comparing patients pre- and post-RT.

The effect of RT on periodontal health is dose-dependent and is associated with worsened periodontal health following the initiation of RT [91]. Independent of the risk of tooth-loss, periodontal disease is relevant to the management of the oncology patients as it has been linked to an increased risk of ORN [88] and also to oral mucositis (OM) [92, 93]. Pre-existing periodontitis, which is common in adults, is likely to worsen with cancer treatment. Furthermore, progressive periodontitis may lead to the need for tooth extraction which may itself result in ORN. It should also be noted that early malignant lesions can mimic periodontitis [94, 95] and expert evaluation by an oral health professional may facilitate a proper diagnosis.

Current recommendations state that patients be examined and treated by a dentist who is aware of the planned cancer therapy and of oral issues before, during, and following cancer therapy [82]. Periodontal disease is the primary cause of tooth loss in adults and extractions of teeth with severely compromised periodontium may be

required before the initiation of oncology treatment - particularly in a region of planned high-dose RT. Teeth that have periodontal attachment loss and teeth that are anticipated to require surgical management in the future within the planned high-dose RT fraction should be extracted prior to RT. Teeth involved may have mobility, or periodontal pockets that require full dental examination to be identified. A lifelong commitment to preventative oral health management is required to minimize the risk of worsening periodontitis which could require a tooth extraction with the associated risks of ORN (discussed immediately below).

Oral complications of head and neck radiotherapy in elderly patients

Elderly patients represent a unique subset of patients in whom acute and late adverse sequelae of RT can be particularly challenging. Increasing age is associated with increased risk of severe late toxicity, such as dysphagia, aspiration pneumonia, and long-term feeding tube dependence on prospective RTOG protocols [96]. However, there is limited prospective data specifically comparing oral toxicity in elderly patients undergoing RT to what is observed in younger patients. Furthermore, there is no consensus on the definition of elderly with some defining it as 70 years or older while others use a 65-years cut-off [97–99]. Most comparative data comes from retrospective case series, with conflicting conclusions. In a study of patients enrolled on EORTC trials from 1980 to 1995, those 65 years of age and older had higher grade 3–4 mucositis during radiation than younger patients, but there was no difference in late toxicities including trismus, xerostomia, or dysphagia [97]. However, other series have reported no difference in acute oral complications for elderly and younger patients undergoing radiotherapy [67, 68]. Additionally, higher hospitalization rates for elderly patients and unplanned treatment breaks have been reported in some series, [98, 100, 101] but this appears more commonly due to infectious or renal complications rather than oral complications. In contrast, some major centers have not seen increased hospitalizations or treatment breaks in elderly patients [102]. Thus, further investigation into the impact of age and comorbidity on radiation complications is warranted.

Osteoradionecrosis

Osteoradionecrosis (ORN) is the result of ischemic necrosis of the bones associated with soft tissue necrosis without the presence of tumor [53]. Histopathological findings include a pre-fibrotic phase with increased endothelial cells activity and inflammation, a subsequent phase

characterized by abnormal fibroblastic activity, and a final phase with characteristic fibroatrophic remodeling and loss of osteocytes in bone [54]. Histopathological findings include: initially hyperemia, endarteritis and thrombosis, followed by cell loss, hypovascularity, increase in bone marrow fat and fibrosis [55]. The histomorphometric analysis was statistically significant for hypocellularity, hypovascularity and fibrosis [55].

Reports have indicated a variable incidence of ORN between 4 and 37% [56] with declining risk in modern series associated with advances in RT. When three-dimensional RT and IMRT became available, the observed average incidence of ORN decreased to lower than 5% [57]. In a systematic review, the weighted prevalence of ORN was 7.4% in conventional RT, 5.1% with IMRT, 6.8% with chemoradiation (CRT), and 5.3% with brachytherapy [58]. In addition, the lower incidence of ORN has also been attributed to improved preventive oral care [59]. When oral hygiene is poor and other local factors are present, such as ill-fitting dentures or post-RT dentoalveolar surgery, the incidence can exceed 25% [60].

ORN has been classified based on treatment response to Hyperbaric Oxygen Therapy (HBO) [61]; on the clinical behavior of ORN whether healed, chronic but non-progressive, or active progressive [62]; or the severity grade according to the anatomical extent [63]. Other classifications include the extent of ORN and symptoms [64].

ORN may cause significant loss of quality of life particularly in advanced stages [65]. Risk factors associated with ORN include tumor-related factors, treatment-related factors, and patient-related factors [55]. Some of these factors include the presence of dental disease (inflammation and infection), the need for pre-irradiation HNC surgery and dental surgery, oral health and hygiene [53]. Others factors predicting ORN include increased RT fraction size, increased total RT dose to the mandible, and other factors such as the extent of the tumor, proximity with bone, bone invasion and the need for pre-radiation bone resection [66]. Males age 55 or older with history of tobacco and alcohol use are more frequently affected [56, 67]. The mandible is more commonly affected than the maxilla. While most ORN cases develop in the first three years after completion of RT [53, 63, 68], it can occur at any time following RT.

Treating existing oral disease and stabilizing oral health before and following cancer therapy may decrease the risk of ORN. The goal is to minimize the need of invasive interventions (e.g., extraction) and dental inflammatory disease/infection during and after RT for the life of the patient. Evaluation by an experienced dental provider and integration of care with the oncology team will determine ideal oral care prior to starting radiation therapy.

Management protocols proposed to treat ORN include conservative therapy with medication, ultrasound, HBO, and surgical resection and reconstruction for nonresponding, advanced stage ORN [53]. The characterization of fibrosis as part of the pathogenesis of ORN has led to the use of anti-radiation fibrosis drugs such as pentoxifylline, tocopherol, and clodronate [69]. Antioxidant therapy has also been proposed [70]. New experimental studies have assessed bone marrow-derived stem cells and bone morphogenetic protein-2 to facilitate osseous healing in cases of ORN [71]. Other approaches include promotion of bone and soft tissue repair using low-level laser therapy [72]. Resection and vascular graft reconstruction are considered in cases with pathologic fracture or threatening fracture with progression despite nonsurgical therapy. The best approach to treating ORN is prevention. Additional prospective studies are needed to determine long-term success of ORN management. There is little evidence other than clinical case series to support the use of these treatment modalities including the use of HBO [73]. A controlled trial of HBO for the management of mandibular ORN showed it to be without merit [74].

Conclusion

This paper outlines some of the key dental, oral soft tissue, and neurological complications in HNC treated with RT. Oral care must include the full trajectory of the cancer journey from diagnosis to survivorship. Preventing, assessing, and managing oral complications throughout the active continuum of care are required to promote the best possible patient QOL. The pretreatment dental management should be directed at necessary assessment including complete oral, dental, and periodontal examination and baseline range of jaw movement and saliva production. The baseline measures allow evaluation of changes that may occur following treatment and indicate potential need for intervention. Standard preventive oral care should be provided. Acute oral complications may be more easily recognized than the ongoing issues common in survivors, but both represent a challenge to the oncology team. Integrated pretreatment oral and dental evaluation of HNC patients is the best approach to achieving the best possible clinical outcomes. It is also clear that a life-long access to expert oral health care is critical for HNC survivors, as loss of motility and sensory disturbances may remain permanent.

One of the key challenges in achieving optimal integrated oral health care for HNC patients is that not all cancer centers have integrated oral and dental care programs. Some centers obtain services from general hospital dentistry programs, often delivered by one-year general practice residents, with limited supervision. Some of the

HNC patients are seen by community oral health providers, the majority of which have no training or experience in oncology and are not integrated with the oncology team and may not be prepared to treat the dental/oral needs [103]. Recommendations for identifying community resources that may assist the cancer center in obtaining oral care have been discussed elsewhere [104].

Conflict of Interest

The authors disclose no conflict of interest.

References

1. Duncan, G. G., J. B. Epstein, D. Tu, S. El Sayed, A. Bezjak, J. Ottaway, et al. 2005. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. *Head Neck* 27:421–428.
2. Sonis, S. T., J. P. Eilers, J. B. Epstein, F. G. LeVeque, W. H. Liggett, M. T. Mulagha, et al. 1999. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. *Cancer* 85:2103–2113.
3. Lalla, R. V., D. P. Saunders, and D. E. Peterson. 2014. Chemotherapy or radiation-induced oral mucositis. *Dent. Clin. North Am.* 58:341–349.
4. Ang, K. K., Q. Zhang, D. I. Rosenthal, P. F. Nguyen-Tan, E. J. Sherman, R. S. Weber, et al. 2014. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. *J. Clin. Oncol.* 32:2940–2950.
5. Heutte, N., L. Plisson, M. Lange, V. Prevost, and E. Babin. 2014. Quality of life tools in head and neck oncology. *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 131:33–47.
6. Gussgard, A. M., A. J. Hope, A. Jokstad, H. Tenenbarum, and R. Wood. 2014. Assessment of cancer therapy-induced oral mucositis using a patient-reported oral mucositis experience questionnaire. *PLoS ONE* 9:e91733.
7. Lalla, R. V., S. T. Sonis, and D. E. Peterson. 2008. Management of oral mucositis in patients with cancer. *Dent. Clin. North Am.* 52:61–77. <https://doi.org/10.1016/j.cden.2007.10.002>.
8. Lalla, R. V., N. Treister, T. Sollecito, B. Schmidt, L. L. Patton, K. Mohammadi, et al. 2017. Oral complications at six months after radiation therapy for head and neck cancer. *Oral Dis.* [Epub ahead of print] PMID: 28675770. <https://doi.org/10.1111/odi.12710>.
9. Elting, L. S., C. D. Cooksley, M. S. Chambers, and A. S. Garden. 2007. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. *Int. J. Radiat. Oncol. Biol. Phys.* 68:1110–1120.
10. Rosenthal, D. I. 2007. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. *J. Support. Oncol.* 5(9 Suppl 4):23–31.
11. Lalla, R. V., J. Bowen, A. Barasch, L. Elting, J. Epstein, D. M. Keefe, et al. 2014. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer* 120:1453–1461.
12. Leenstra, J. L., R. C. Miller, R. Qin, J. A. Martenson, K. J. Dornfeld, J. D. Bearden, et al. 2014. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). *J. Clin. Oncol.* 32:1571–1577.
13. Nicolatou-Galitis, O., T. Sarri, J. Bowen, Palma M. Di, V. E. Kouloulas, P. Niscola, et al. 2013. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. *Support. Care Cancer* 21:3179–3189.
14. Le, Q. T., H. E. Kim, C. J. Schneider, G. Muraközy, K. Skladowski, S. Reinisch, et al. 2011. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. *J. Clin. Oncol.* 29:2808–2814.
15. Sheibani, K. M., A. R. Mafi, S. Moghaddam, F. Taslimi, A. Amiran, and A. Ameri. 2015. Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. *Asia Pac. J. Clin. Oncol.* 11:22–27.
16. Allison, R. R., A. A. Ambrad, Y. Arshoun, R. J. Carmel, D. F. Ciuba, E. Feldman, et al. 2014. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. *Cancer* 120:1433–1440.
17. McGuire, D. B., J. S. Fulton, J. Park, C. G. Brown, M. E. Correa, J. Eilers, et al. 2013. Systematic review of basic oral care for the management of oral mucositis in cancer patients. *Support. Care Cancer* 21:3165–3177.
18. Migliorati, C., I. Hewson, R. V. Lalla, H. S. Antunes, C. L. Estilo, B. Hodgson, et al. 2013. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. *Support. Care Cancer* 21:333–341.
19. Lopes, N. N., H. Plapler, M. C. Chavantes, R. V. Lalla, E. M. Yoshimura, and M. T. Alves. 2009. Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral

- mucositis in hamsters: evaluation of two low-intensity laser protocols. *Support. Care Cancer* 17:1409–1415.
20. Lopes, N. N., H. Plapler, R. V. Lalla, M. C. Chavantes, E. M. Yoshimura, M. A. da Silva, et al. 2010. Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters. *Lasers Surg. Med.* 42:546–552.
 21. Yarom, N., A. Ariyawardana, A. Hovan, A. Barasch, V. Jarvis, S. B. Jensen, et al. 2013. Systematic review of natural agents for the management of oral mucositis in cancer patients. *Support. Care Cancer* 21:3223–3232.
 22. Jensen, S. B., V. Jarvis, Y. Zadik, A. Barasch, A. Ariyawardana, A. Hovan, et al. 2013. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. *Support. Care Cancer* 21:3223–3232.
 23. Saunders, D. P., J. B. Epstein, S. Elad, J. Allemano, P. Bossi, M. D. van de Wetering, et al. 2013. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. *Support. Care Cancer* 21:3191–3207.
 24. Mun, M., T. Yap, A. D. Alnuaimi, G. G. Adams, and M. J. McCullough. 2016. Oral candidal carriage in asymptomatic patients. *Aust. Dent. J.* 61:190–195. <https://doi.org/10.1111/adj.12335>.
 25. Pagani, J. L., J. P. Chave, C. Casjka, M. P. Glauser, and J. Bille. 2002. Efficacy, tolerability and development of resistance in HIV positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. *J. Antimicrob. Chemother.* 50:231–240.
 26. Bensadoun, R. J., D. Daoud, L. Bastit, B. El Gueddari, C. Allavena, A. Benidder, et al. 2008. Comparison of the efficacy and safety of miconazole Lauriad® tablets to those of miconazole gel in the treatment of oropharyngeal candidiasis: a controlled multicenter, randomised, phase III trial in patients treated with radiotherapy for head and neck cancer. *Cancer* 112:204–211.
 27. Finlay, P. M., M. D. Richardson, and A. G. Robertson. 1996. A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. *Br. J. Oral Maxillofac. Surg.* 34:23–25.
 28. Kinirons, M. J., P. Fleming, and D. Boyd. 1995. Dental caries experience of children in remission from acute lymphoblastic leukaemia in relation to the duration of treatment and the period of time in remission. *Int. J. Paediatr. Dent.* 5:169–172.
 29. Phillips, S. M., and T. M. Dellinger. 2005. Dental decay due to xerostomia and nystatin. *Ann. Pharmacother.* 39:1758.
 30. El-Asmar, J., R. Gonzalez, R. Bookout, A. Mishra, and M. A. Kharfan-Dabaja. 2016. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. *Hematol. Oncol. Stem Cell Ther.* 9:157–161.
 31. Charlier, C., E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, et al. 2006. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? *J. Antimicrob. Chemother.* 57:384–410.
 32. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Jr Benjamin, T. F. Calandra, J. E. Jr Edwards, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* 1:503–535.
 33. Nicolatou-Galitis, O., A. Velegraki, A. Sotiropoulou-Lontou, K. Dardoufas, V. Kouloulis, K. Kyprianou, et al. 2006. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. *Support. Care Cancer* 14:44–51.
 34. Mann, P. A., P. M. McNicholas, A. S. Chau, R. Patel, C. Mendrick, A. J. Ullmann, et al. 2009. Impact of antifungal prophylaxis on colonization and azole susceptibility of *Candida* species. *Antimicrob. Agents Chemother.* 53:5026–5034.
 35. Clarkson, J. E., H. V. Worthington, and O. B. Eden. 2007. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. *Cochrane Database Syst. Rev.*:CD003807.
 36. Ellepola, A. N., and L. P. Samaranayake. 2001. Adjunctive use of chlorhexidine in oral candidoses: a review. *Oral Dis.* 7:11–17.
 37. Ganzer, H., R. Touger-Decker, L. Byham-Gray, B. A. Murphy, and J. B. Epstein. 2015. The eating experience after treatment for head and neck cancer: a review of the literature. *Oral Oncol.* 51:634–642.
 38. Dropcho, E. J. 2010. Neurotoxicity of radiation therapy. *Neurol. Clin.* 28:217–234.
 39. Epstein, J. B., S. Emerton, D. A. Kolbinson, N.D. Le, N. Phillips, and P. Stevenson-Moore, et al. 1999. Quality of life and oral function following radiotherapy for head and neck cancer. *Head Neck* 21:1–11.
 40. Boyette-Davis, J. A., E. T. Walters, and P. M. Dougherty. 2015. Mechanisms involved in the development of chemotherapy-induced neuropathy. *Pain Manag.* 5:285–296.
 41. Boers-Doets, C. B., J. E. Raber-Durlacher, N. S. Treister, J. B. Epstein, A. B. Arends, D. R. Wiersma, et al. 2013. Mammalian target of rapamycin inhibitor-associated stomatitis. *Future Oncol.* 9:1883–1892.
 42. Jackson, L. K., D. B. Johnson, J. A. Sosman, B. A. Murphy, and J. B. Epstein. 2015. Oral health in

- oncology: impact of immunotherapy. *Support. Care Cancer* 23:1–3.
43. Vadalouca, A., E. Raptis, E. Moka, P. Zis, P. Sykioti, and I. Siafaka. 2012. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. *Pain Pract.* 12:219–251.
 44. Hunt, S. P., and P. W. Mantyh. 2001. The molecular dynamics of pain control. *Nat. Rev. Neurosci.* 2:83–91.
 45. Epstein, J. B., J. Thariat, R. J. Bensadoun, A. Barasch, B. A. Murphy, L. Kolnick, et al. 2012. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. *CA Cancer J. Clin.* 62:400–422.
 46. Ing, J. W. 2017. Head and neck cancer pain. *Otolaryngol. Clin. North Am.* 50:793–806. <https://doi.org/10.1016/j.otc.2017;04.001>.
 47. Holscher, T., A. Seibt, S. Appold, W. Dörr, T. Herrmann, K. B. Hüttenbrink, and T. Hummel. 2005. Effects of radiotherapy on olfactory function. *Radiother. Oncol.* 77:157–163.
 48. Leitzen, C., S. Herberhold, T. Wilhelm-Buchstab, S. Garbe, T. Müdder, and F. Schoroth, et al. 2012. Changes in taste during IMRT Radiotherapy for Head and Neck Cancer Patients. *Strahlentherapie Onkologie* 188:184–185.
 49. Hovan, A. J., P. M. Williams, P. Stevenson-Moore, Y. B. Wahlin, K. E. Ohn, and L. S. Elting, et al. 2010. A systematic review of dysgeusia induced by cancer therapies. *Support. Care Cancer* 18:1081–1087.
 50. Yamashita, H., K. Nakagawa, Y. Hosoi, A. Kurokawa, Y. Fukuda, and I. Matsumoto, et al. 2009. Umami taste dysfunction in patients receiving radiotherapy for head and neck cancer. *Oral Oncol.* 45:e19–e23.
 51. Epstein, J. B., G. Smutzer, and R. L. Doty. 2016. Understanding the impact of taste changes in oncology care. *Support. Care Cancer* 24:1917–1931.
 52. Ripamonti, C., and F. Fulfaro. 1998. Taste alterations in cancer patients. *J. Pain Symptom Manag.* 16:349–351.
 53. Mossman, K., A. Shatzman, and J. Chencharick. 1982. Long-term effects of radiotherapy on taste and salivary function in man. *Int. J. Radiat. Oncol. Biol. Phys.* 8:991–997.
 54. Zheng, W. K., A. Inokuchi, T. Yamamoto, and S. Komiyama. 2002. Taste dysfunction in irradiated patients with head and neck cancer. *Fukuoka Igaku Zasshi* 93:64–76.
 55. Panayiotou, H., S. C. Small, J. H. Hunter, and R. M. Culpepper. 1995. Sweet taste (dysgeusia). The first symptom of hyponatremia in small cell carcinoma of the lung. *Arch. Intern. Med.* 155:1325–1328.
 56. Bromley, S. M., and R. L. Doty. 2015. Clinical disorders affecting taste: an update. Pp. 887–910 in R. L. Doty, ed. *Handbook of Olfaction and Gustation*, 3rd ed. John Wiley & Sons, Hoboken, NJ.
 57. Doty, R. L., M. Shah, and S. M. Bromley. 2008. Drug-induced taste disorders. *Drug Saf.* 31:199–215.
 58. Mossman, K. L., J. D. Chencharick, A. C. Scheer, W. P. Walker, R. D. Ornitz, and C. C. Rogers, et al. 1979. Radiation-induced changes in gustatory function: comparison of effects of neutron and photon irradiation. *Int. J. Radiat. Oncol. Biol. Phys.* 5:521–528.
 59. Shi, H. B., M. Masuda, T. Umezaki, Y. Kuratomi, Y. Kumamoto, and T. Yamamoto, et al. 2004. Irradiation impairment of umami taste in patients with head and neck cancer. *Auris Nasus Larynx* 31:401–406.
 60. Halyard, M. Y., A. Jatoi, J. A. Sloan, J. D. Bearden III, S. A. Vora, and P. J. Atherton, et al. 2007. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double blind, placebo-controlled trial from the north central cancer treatment group (N01C4). *Int. J. Radiat. Oncol. Biol. Phys.* 67:1318–1322.
 61. Thorne, T., K. Olson, and W. Wismer. 2015. A state-of-the-art review of the management and treatment of taste and smell alterations in adult oncology patients. *Support. Care Cancer* 23:2843–2851.
 62. Goldstein, M., W. G. Maxymiw, B. J. Cummings, and R. E. Wood. 1999. The effects of antitumor irradiation on mandibular opening and mobility: a prospective study of 58 patients. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 88:365–373.
 63. Jeremic, G., V. Venkatesan, A. Hallock, D. Scott, A. Hammond, N. Read, et al. 2011. Trismus following treatment of head and neck cancer. *J. Otolaryngol. Head Neck Surg.* 40:323–329.
 64. Dijkstra, P. U., W. W. Kalk, and J. L. Roodenburg. 2004. Trismus in head and neck oncology: a systematic review. *Oral Oncol.* 40:879–889.
 65. Dijkstra, P. U., P. M. Huisman, and J. L. Roodenburg. 2006. Criteria for trismus in head and neck oncology. *Int. J. Oral Maxillofac. Surg.* 35:337–342.
 66. Bensadoun, R. J., D. Riesenbeck, P. B. Lockhart, L. S. Elting, F. K. Spijkervet, and M. T. Brennan. 2010. A systematic review of trismus induced by cancer therapies in head and neck cancer patients. *Support. Care Cancer* 18:1033–1038.
 67. Zecha, J. A., J. E. Raber-Durlacher, R. G. Nair, J. B. Epstein, S. Elad, M. R. Hamblin, et al. 2016. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. *Support. Care Cancer* 24:2793–2805.
 68. Escoda-Francolí, J., A. Rodríguez-Rodríguez, S. Pérez-García, J. Gargallo-Albiol, and C. Gay-Escoda. 2011.

- Dental implications in oral cancer patients. *Med. Oral Patol. Oral Cir. Bucal.* 16:e508–e513.
69. Dowd, F. J. 1999. Saliva and dental caries. *Dent. Clin. North Am.* 43:579–597.
 70. Michelet, M. 2012. Caries and periodontal disease in cancer survivors. *Evid. Based Dent.* 13:70–73. <https://doi.org/10.1038/sj.ebd.6400870>.
 71. Hey, J., J. Seidel, R. Schweyen, Y. Paelecke-Habermann, D. Vordermark, C. Gernhardt, et al. 2013. The influence of parotid gland sparing on radiation damages of dental hard tissues. *Clin. Oral Investig.* 17:1619–1625. <https://doi.org/10.1007/s00784-012-0854-6>.
 72. Gomez, D. R., C. L. Estilo, S. L. Wolden, M. J. Zelefsky, D. H. Kraus, R. J. Wong, et al. 2011. Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 81:e207–e213.
 73. Lin, A., H. M. Kim, J. E. Terrell, L. A. Dawson, J. A. Ship, and A. Eisbruch. 2003. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. *Int. J. Radiat. Oncol. Biol. Phys.* 57:61–70.
 74. Aguiar, G. P., B. C. Jham, C. S. Magalhães, L. G. Sensi, and A. R. Freire. 2009. A review of the biological and clinical aspects of radiation caries. *J. Contemp. Dent. Pract.* 10:83–89.
 75. Lieshout, H. F., and C. P. Bots. 2014. The effect of radiotherapy on dental hard tissue—a systematic review. *Clin. Oral Investig.* 18:17–24. <https://doi.org/10.1007/s00784-013-1034-z>.
 76. Silva, A. R., F. A. Alves, A. Antunes, M. F. Goes, and M. A. Lopes. 2009. Patterns of demineralization and dentin reactions in radiation-related caries. *Caries Res.* 43:43–49. <https://doi.org/10.1159/000192799>.
 77. Silva, A. R., F. A. Alves, S. B. Berger, M. Giannini, M. F. Goes, and M. A. Lopes. 2010. Radiation-related caries and early restoration failure in head and neck cancer patients. A polarized light microscopy and scanning electron microscopy study. *Support. Care Cancer* 18:83–87. <https://doi.org/10.1007/s00520-009-0633-3>.
 78. Al-Nawas, B., and K. A. Grötz. 2006. Prospective study of the long term change of the oral flora after radiation therapy. *Support. Care Cancer* 14:291–296.
 79. Chambers, M. S., J. R. Mellberg, H. J. Keene, O. J. Bouwsma, A. S. Garden, T. Sipos, et al. 2006. Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 1: fluorides. *Oral Oncol.* 42:934–945.
 80. Chambers, M. S., J. R. Mellberg, H. J. Keene, O. J. Bouwsma, A. S. Garden, T. Sipos, et al. 2006. Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: phase I study. *Oral Oncol.* 42:946–953.
 81. Deng, J., L. Jackson, J. B. Epstein, C. A. Migliorati, and B. A. Murphy. 2015. Dental demineralization and caries in patients with head and neck cancer. *Oral Oncol.* 51:824–831. <https://doi.org/10.1016/j.oraloncology.2015.06.009>.
 82. Hong, C. H., J. J. Napeñas, B. D. Hodgson, M. A. Stokman, V. Mathers-Stauffer, L. S. Elting, et al. 2010. A systematic review of dental disease in patients undergoing cancer therapy. *Support. Care Cancer* 18:1007–1021. <https://doi.org/10.1007/s00520-010-0873-2>.
 83. Meurman, J. H., and L. Grönroos. 2010. Oral and dental health care of oral cancer patients: hyposalivation, caries and infections. *Oral Oncol.* 46:464–467. <https://doi.org/10.1016/j.oraloncology.2010.02.025>.
 84. Aframian, D. J., M. Helcer, D. Livni, and A. Markitziu. 2006. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. *Oral Dis.* 12:297–300.
 85. Lajer, C., C. Buchwald, B. Nauntofte, L. Specht, A. Bardow, and T. Jensdottir. 2009. Erosive potential of saliva stimulating tablets with and without fluoride in irradiated head and neck cancer patients. *Radiother. Oncol.* 93:534–538. <https://doi.org/10.1016/j.radonc.2009.06.028>.
 86. Sennhenn-Kirchner, S., F. Freund, S. Grundmann, A. Martin, M. Borg-von Zepelin, H. Christiansen, et al. 2009. Dental therapy before and after radiotherapy—an evaluation on patients with headand neck malignancies. *Clin. Oral Investig.* 13:157–164. <https://doi.org/10.1007/s00784-008-0229-1>.
 87. Husein, A. B., C. J. Butterworth, M. S. Ranka, A. Kwasnicki, and S. N. Rogers. 2011. A survey of general dental practitioners in the North West of England concerning the dental care of patients following head and neck radiotherapy. *Prim. Dent. Care* 18:59–65. <https://doi.org/10.1308/135576111795162910>.
 88. Katsura, K., K. Sasai, K. Sato, M. Saito, H. Hoshina, and T. Hayashi. 2008. Relationship between oral health status and development of osteoradionecrosis of the mandible: a retrospective longitudinal study. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 105:731–738. <https://doi.org/10.1016/j.tripleo.2007.10.011>.
 89. Laheij, A. M., and J. J. de Soet. 2014. Can the oral microflora affect oral ulcerative mucositis? *Curr. Opin. Support Palliat. Care* 8:180–187. <https://doi.org/10.1097/SPC.0000000000000053>.
 90. Ammajan, R. R., R. Joseph, R. Rajeev, K. Choudhary, and K. Vidhyadharan. 2013. Assessment of periodontal changes in patients undergoing radiotherapy for head and neck malignancy: a hospital-based study. *J. Cancer. Res. Ther.* 9:630–637. <https://doi.org/10.4103/0973-1482.126461>.

91. Hommeez, G. M., G. O. De Meerleer, W. J. De Neve, and R. J. De Moor. 2012. Effect of radiation dose on the prevalence of apical periodontitis—a dosimetric analysis. *Clin. Oral Investig.* 16:1543–1547. <https://doi.org/10.1007/s00784-011-0665-1>.
92. Khaw, A., R. Logan, D. Keefe, and M. Bartold. 2014. Radiation-induced oral mucositis and periodontitis - proposal for an inter-relationship. *Oral Dis.* 20:e7–e18. <https://doi.org/10.1111/odi.12199>.
93. Khaw, A., S. Liberali, R. Logan, D. Keefe, and P. M. Bartold. 2014. Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study. *Support. Care Cancer* 22:2119–2125. <https://doi.org/10.1007/s00520-014-2186-3>.
94. Yamada, T., K. Mishima, A. Ota, N. Moritani, T. Matsumura, N. Katase, et al. 2010. A case of ATLL (adult T-cell leukemia/lymphoma) mimicking odontogenic infection. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 109:e51–e55. <https://doi.org/10.1016/j.tripleo.2010.02.021>.
95. Saund, D., S. Kotecha, J. Rout, and T. Dietrich. 2010. Non-resolving periapical inflammation: a malignant deception. *Int. Endod. J.* 43:84–90. <https://doi.org/10.1111/j.1365-2591.2009.01644.x>.
96. Machtay, M., J. Moughan, A. Trotti, A. S. Garden, R. S. Weber, J. S. Cooper, et al. 2008. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. *J. Clin. Oncol.* 26:3582–3589. <https://doi.org/10.1200/JCO.2007.14.8841>.
97. Pignon, T., J. C. Horiot, W. Van den Bogaert, M. Van Glabbeke, and P. Scalliet. 1996. No age limit for radical radiotherapy in head and neck tumours. *Eur. J. Cancer* 32A:2075–2081.
98. Michal, S. A., D. J. Adelstein, L. A. Rybicki, C. P. Rodriguez, J. P. Saxton, and B. G. Wood, et al. 2012. Multiagent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. *Head Neck* 34:1147–1152.
99. Merlano, M. C., M. Monteverde, I. Colantonio, N. Denaro, C. Lo Nigro, and G. Natoli, et al. 2012. Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. *Oral Oncol.* 48:1051–1057.
100. Daly, M. E., D. H. Lau, D. G. Farwell, Q. Luu, P. J. Donald, and A. M. Chen. 2013. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer. *Am. J. Otolaryngol.* 34:631–635.
101. Maggiore, R. J., E. K. Curran, M. E. Witt, D. J. Haraf, E. E. Vokes, and E. E. Cohen. 2013. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. *J. Geriatr. Oncol.* 4:327–333. <https://doi.org/10.1016/j.jgo.2013.05.003>.
102. Huang, S. H., B. O'Sullivan, J. Waldron, G. Lockwood, A. Bayley, J. Kim, et al. 2011. Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. *Int. J. Radiat. Oncol. Biol. Phys.* 79:46–51.
103. Epstein, J. B., I. R. Parker, M. S. Epstein, A. Gupta, S. Kutis, and D. M. Witkowski. 2007. A survey of National Cancer Institute-designated comprehensive cancer centers' oral health supportive care practices and resources in the USA. *Support. Care Cancer* 15:357–362.
104. Epstein, J. B., P. Guneri, and A. Barasch. 2014. Appropriate and necessary oral care for people with cancer: guidance to obtain the right treatment at the right time. *Support. Care Cancer* 22:1981–1988. <https://doi.org/10.1007/s00520-014-2228-x>.